JPH04506796A - ウィルス感染及び腫瘍の処理のためのＤ―アスパラギン酸β―ヒドロキサメート - Google Patents
ウィルス感染及び腫瘍の処理のためのＤ―アスパラギン酸β―ヒドロキサメートInfo
- Publication number
- JPH04506796A JPH04506796A JP2507392A JP50739290A JPH04506796A JP H04506796 A JPH04506796 A JP H04506796A JP 2507392 A JP2507392 A JP 2507392A JP 50739290 A JP50739290 A JP 50739290A JP H04506796 A JPH04506796 A JP H04506796A
- Authority
- JP
- Japan
- Prior art keywords
- dah
- treatment
- aspartic acid
- directed
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 15
- 230000009385 viral infection Effects 0.000 title claims description 11
- 208000036142 Viral infection Diseases 0.000 title claims description 10
- ZBYVTTSIVDYQSO-REOHCLBHSA-N beta-L-aspartylhydroxamic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)NO ZBYVTTSIVDYQSO-REOHCLBHSA-N 0.000 title description 107
- 241001430294 unidentified retrovirus Species 0.000 claims description 14
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 13
- 208000030507 AIDS Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 4
- 229930182846 D-asparagine Natural products 0.000 claims description 4
- 238000006184 hydroxyamination reaction Methods 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- WXFCDLWCQIARFW-SCSAIBSYSA-N (3r)-3-amino-4-ethoxy-4-oxobutanoic acid Chemical compound CCOC(=O)[C@H](N)CC(O)=O WXFCDLWCQIARFW-SCSAIBSYSA-N 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims 2
- 241000700605 Viruses Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 18
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 12
- 102100034343 Integrase Human genes 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000003924 normoblast Anatomy 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 208000008601 Polycythemia Diseases 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 231100000816 toxic dose Toxicity 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 238000011765 DBA/2 mouse Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101000941628 Canis lupus familiaris Cytochrome P450 1A1 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- -1 β-ethyl Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8905744A FR2646348A1 (fr) | 1989-04-28 | 1989-04-28 | D-aspartique acide-hydroxamate en tant que medicament |
| FR89/05744 | 1989-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04506796A true JPH04506796A (ja) | 1992-11-26 |
Family
ID=9381297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2507392A Pending JPH04506796A (ja) | 1989-04-28 | 1990-04-27 | ウィルス感染及び腫瘍の処理のためのＤ―アスパラギン酸β―ヒドロキサメート |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0470144B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH04506796A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE121935T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU660916B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2050936A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69019148T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0470144T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2072431T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2646348A1 (cg-RX-API-DMAC7.html) |
| OA (1) | OA09519A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1990013291A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6018752B2 (ja) * | 2009-09-29 | 2016-11-02 | 株式会社 資生堂 | 抗酸化組成物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705522A (en) * | 1995-09-15 | 1998-01-06 | Compagnie De Developpement Aguettant S.A. | Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2600256B1 (fr) * | 1986-06-19 | 1988-09-16 | Inst Nat Sante Rech Med | Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus |
-
1989
- 1989-04-28 FR FR8905744A patent/FR2646348A1/fr active Granted
-
1990
- 1990-04-27 DK DK90907159.9T patent/DK0470144T3/da active
- 1990-04-27 CA CA002050936A patent/CA2050936A1/fr not_active Abandoned
- 1990-04-27 EP EP90907159A patent/EP0470144B1/fr not_active Expired - Lifetime
- 1990-04-27 WO PCT/FR1990/000307 patent/WO1990013291A1/fr not_active Ceased
- 1990-04-27 JP JP2507392A patent/JPH04506796A/ja active Pending
- 1990-04-27 AU AU56575/90A patent/AU660916B2/en not_active Ceased
- 1990-04-27 DE DE69019148T patent/DE69019148T2/de not_active Expired - Fee Related
- 1990-04-27 AT AT90907159T patent/ATE121935T1/de not_active IP Right Cessation
- 1990-04-27 ES ES90907159T patent/ES2072431T3/es not_active Expired - Lifetime
-
1991
- 1991-10-25 OA OA60087A patent/OA09519A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6018752B2 (ja) * | 2009-09-29 | 2016-11-02 | 株式会社 資生堂 | 抗酸化組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE121935T1 (de) | 1995-05-15 |
| ES2072431T3 (es) | 1995-07-16 |
| WO1990013291A1 (fr) | 1990-11-15 |
| OA09519A (fr) | 1992-11-15 |
| CA2050936A1 (fr) | 1990-10-29 |
| DK0470144T3 (da) | 1995-10-02 |
| DE69019148D1 (de) | 1995-06-08 |
| AU5657590A (en) | 1990-11-29 |
| EP0470144A1 (fr) | 1992-02-12 |
| EP0470144B1 (fr) | 1995-05-03 |
| FR2646348B1 (cg-RX-API-DMAC7.html) | 1994-04-22 |
| DE69019148T2 (de) | 1995-08-31 |
| AU660916B2 (en) | 1995-07-13 |
| FR2646348A1 (fr) | 1990-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5521161A (en) | Method of treating HIV in humans by administration of ddI and hydroxycarbamide | |
| JPS6277334A (ja) | Ａｉｄｓの予防及び治療剤 | |
| US20080300253A1 (en) | Treatment of inflammatory disorders with praziquantel | |
| BRPI0017067B1 (pt) | inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto | |
| JPH03504122A (ja) | 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類 | |
| JPH07252147A (ja) | クマリン誘導体を含有する薬剤 | |
| EP0424193B1 (en) | Use of actinonin for the manufacture of a medicament for angiogenesis inhibition | |
| JPH08503699A (ja) | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 | |
| JPH04506796A (ja) | ウィルス感染及び腫瘍の処理のためのＤ―アスパラギン酸β―ヒドロキサメート | |
| JPH07502975A (ja) | 抗腫瘍及び抗―レトロウィルス剤として有用なアデノシンジホスホリボースポリメラーゼ結合性ニトロソ芳香族化合物 | |
| JP3102945B2 (ja) | 肝炎治療剤 | |
| US5571839A (en) | D-aspartic acid β-hydroxamate for the treatment of viral infections and tumors | |
| JP2761876B2 (ja) | 新規化合物、その製造方法及びその用途 | |
| JPH02501220A (ja) | 芳香族多環式ジオンを含有する抗ウイルス性薬剤及びレトロウイルス感染治療方法 | |
| CN117205188A (zh) | 维生素k4在制备治疗黑色素瘤的药物中的应用 | |
| AU706703B2 (en) | 1,3-dicarboxylic germanium complex and its therapeutic use | |
| JPH02501798A (ja) | 鉄を放出するモノカイン類 | |
| VENGRIS et al. | Polymeric drugs: direct compared with indirect inhibition of leukemia virus replication in mice | |
| JP2002535371A (ja) | リバビリンによる免疫応答の調節 | |
| EP1607091A1 (en) | Antihepatitis c virus agent and anti-hiv agent | |
| TW200412989A (en) | Gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium | |
| EP0344643A2 (en) | Antiviral pharmaceutical composition | |
| CN119488525B (zh) | 化合物在制备治疗白血病药物中的用途 | |
| CN100569237C (zh) | 一种抗腺病毒的药物及用途 | |
| CN117510408A (zh) | 抗病毒中药单体蝙蝠葛碱、及其药物组合物和应用 |